Pharmacologic targeting of the dopamine D2 receptor impacts the efficacy of immune checkpoint blockade in melanoma - PubMed
7 hours ago
- #melanoma
- #immune checkpoint inhibitors
- #dopamine D2 receptor
- Pharmacologic modulation of dopamine D2 receptor (D2R) affects immune checkpoint blockade efficacy in melanoma.
- D2R agonist bromocriptine (BRC) accelerated tumor growth and reduced CD8+ T cell infiltration in responder models.
- D2R antagonist metoclopramide (MCP) slowed tumor growth and increased CD8+ T cell infiltration in non-responder models.
- MCP enhanced immune-mediated processes in tumors based on biological sex and improved MHC expression on cancer cells.
- Findings suggest FDA-approved D2R-targeting drugs could be used as cotherapeutics to overcome ICI resistance in advanced melanoma.